tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

KROS Stock Latest News

Keros Therapeutics price target raised to $27 from $23 at Oppenheimer
The FlyKeros Therapeutics price target raised to $27 from $23 at Oppenheimer
1d ago
KROS
Promising Future for Keros Therapeutics: Buy Rating Backed by Strategic Focus and Key Partnerships
PremiumRatings
Promising Future for Keros Therapeutics: Buy Rating Backed by Strategic Focus and Key Partnerships
2d ago
KROS
Keros Therapeutics Reports Strong Revenue Growth
PremiumCompany Announcements
Keros Therapeutics Reports Strong Revenue Growth
2d ago
KROS
Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Financial Uncertainties
PremiumRatings
Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Financial Uncertainties
3d ago
KROS
Keros Therapeutics: Strategic Focus on KER-065 and Financial Position Justifies Hold Rating
PremiumRatings
Keros Therapeutics: Strategic Focus on KER-065 and Financial Position Justifies Hold Rating
3d ago
KROS
Keros Therapeutics reports Q3 EPS (18c), consensus (92c)
PremiumThe FlyKeros Therapeutics reports Q3 EPS (18c), consensus (92c)
3d ago
KROS
Keros Therapeutics to repurchase $194.4M of shares
Premium
The Fly
Keros Therapeutics to repurchase $194.4M of shares
19d ago
KROS
Keros Therapeutics Announces $375M Capital Return Program
Premium
Company Announcements
Keros Therapeutics Announces $375M Capital Return Program
24d ago
8K
KROS
Keros Therapeutics announces share repurchase program
PremiumThe Fly
Keros Therapeutics announces share repurchase program
24d ago
TAK
KROS
Keros Therapeutics Presents Promising Phase 1 Trial Data
PremiumCompany Announcements
Keros Therapeutics Presents Promising Phase 1 Trial Data
2M ago
8K
KROS
Keros Therapeutics presents additional clinical data from KER-065 program
PremiumThe Fly
Keros Therapeutics presents additional clinical data from KER-065 program
2M ago
KROS
Keros Therapeutics CEO to Speak at Healthcare Conferences
PremiumCompany Announcements
Keros Therapeutics CEO to Speak at Healthcare Conferences
2M ago
8K
KROS
ADAR1 Capital sends letter to Keros Therapeutics urging board changes
PremiumThe FlyADAR1 Capital sends letter to Keros Therapeutics urging board changes
3M ago
KROS
Keros Therapeutics Gains FDA Orphan Drug Designation
Premium
Company Announcements
Keros Therapeutics Gains FDA Orphan Drug Designation
3M ago
8K
KROS
Keros Therapeutics granted Orphan Drug designation for KER-065 in DMD
Premium
The Fly
Keros Therapeutics granted Orphan Drug designation for KER-065 in DMD
3M ago
KROS
Keros Therapeutics’ treatment of Duchenne MD granted FDA orphan designation
PremiumThe Fly
Keros Therapeutics’ treatment of Duchenne MD granted FDA orphan designation
3M ago
KROS
Keros Therapeutics Reports Strong Revenue Growth
PremiumCompany Announcements
Keros Therapeutics Reports Strong Revenue Growth
3M ago
KROS
Strategic Focus on KER-065 and Leadership Changes Justify Buy Rating for Keros Therapeutics
PremiumRatings
Strategic Focus on KER-065 and Leadership Changes Justify Buy Rating for Keros Therapeutics
3M ago
KROS
Keros Therapeutics’ Workforce Cuts: Potential Savings vs. Strategic Risks
PremiumCompany Announcements
Keros Therapeutics’ Workforce Cuts: Potential Savings vs. Strategic Risks
3M ago
KROS
Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Pipeline Adjustments
PremiumRatingsKeros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Pipeline Adjustments
3M ago
KROS
Keros Therapeutics to discontinue cibotercept, announces COO departure
Premium
The Fly
Keros Therapeutics to discontinue cibotercept, announces COO departure
3M ago
KROS
Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Prudent Resource Allocation
Premium
Ratings
Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Prudent Resource Allocation
3M ago
KROS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >